UTSI [UTSTARCOM] 6-K: UTStarcom Reports Unaudited GAAP Financial Results for the

[UTStarcom Reports Unaudited GAAP Financial Results for the Third Quarter of 2014 · Third Quarter Revenues Exceeded Previously Provided Expectations- · New Expanded Packet Optical Contract Strengthened Partnership with Chunghwa Telecom - · New CFO Onboard to Bring Unique and Valuable Perspectives to Solidify the Company’s fundamentals - · Two New Executive Onboard to Boost Marketing and Sales in North] [UTStarcom Holdings Corp. Third Quarter 2014 Results NASDAQ: UTSI November 14, 2014 Mr. William Wong, CEO Mr. Min Xu, CFO 1 3 Earnings Call Agenda Update on Operating Progress Our Go-forward Strategy Update on Shareholder Value Initiatives Overview of Third Quarter 2014 Results Company Outlook 1 2 3 4 5 1 Update on Operating Progress 4 Operating Highlights 5 We] [FORM 6-K UTSTARCOM HOLDINGS CORP. Level 6, 28 Hennessy Road, Admiralty, Hong Kong Form 20-F x Form 40-F o o o Yes o No x UTStarcom Holdings Corp.]

By | 2016-03-27T19:19:43+00:00 November 14th, 2014|Categories: Chinese Stocks, UTSI, Webplus ver|Tags: , , , , , |0 Comments

DQ [DAQO NEW ENERGY] 6-K: (Original Filing)

[Daqo New Energy Corp. Announces Third Quarter 2014 Results · Record-high quarterly polysilicon production volume of 1,748 MT in Q3 2014, up from 1,504 MT in Q2 2014 · Record-high quarterly polysilicon shipments of 1,598 MT in Q3 2014, up from 1,436 MT in Q2 2014 · Record-low polysilicon production cost of $13.05/kg in Q3 2014, down from $14.13/kg in] []

By | 2016-03-28T06:56:28+00:00 November 14th, 2014|Categories: Chinese Stocks, DQ, SEC Original|Tags: , , , , , |0 Comments

DQ [DAQO NEW ENERGY] 6-K: Daqo New Energy Corp. Announces Third Quarter 2014

[Daqo New Energy Corp. Announces Third Quarter 2014 Results · Record-high quarterly polysilicon production volume of 1,748 MT in Q3 2014, up from 1,504 MT in Q2 2014 · Record-high quarterly polysilicon shipments of 1,598 MT in Q3 2014, up from 1,436 MT in Q2 2014 · Record-low polysilicon production cost of $13.05/kg in Q3 2014, down from $14.13/kg in] []

By | 2016-03-28T06:57:40+00:00 November 14th, 2014|Categories: Chinese Stocks, DQ, Webplus ver|Tags: , , , , , |0 Comments

LONG [eLong] 6-K: (Original Filing)

[Quarter Unaudited Financial Results eLong Reports Third Quarterly room nights exceed 9 million for the first time in eLong’s history LONG BEIJING, November 12, 2014 /PRNewswire/ -- eLong, Inc. (Nasdaq: Highlights n Hotel room nights stayed in the third quarter n Hotel commission revenue for the third quarter n Net revenues for the third quarter n Mobile bookings * n] []

By | 2016-03-28T09:30:31+00:00 November 14th, 2014|Categories: Chinese Stocks, LONG, SEC Original|Tags: , , , , , |0 Comments

LONG [eLong] 6-K: Quarter Unaudited Financial Results eLong Reports Third Quarterly

[Quarter Unaudited Financial Results eLong Reports Third Quarterly room nights exceed 9 million for the first time in eLong’s history LONG BEIJING, November 12, 2014 /PRNewswire/ -- eLong, Inc. (Nasdaq: Highlights n Hotel room nights stayed in the third quarter n Hotel commission revenue for the third quarter n Net revenues for the third quarter n Mobile bookings * n] []

By | 2016-03-28T09:31:28+00:00 November 14th, 2014|Categories: Chinese Stocks, LONG, Webplus ver|Tags: , , , , , |0 Comments

EVK [Ever-Glory International] 8-K: (Original Filing)

[NANJING, China, Nov. 13, 2014 /PRNewswire/ -- Ever-Glory International Group, Inc. (the "Company" or "Ever-Glory") (NYSE MKT: EVK), a leading apparel supply chain manager and retailer based in China, today reported its financial results for the third quarter ended September 30, 2014. Total sales for the quarter were $139.9 million, an increase of 31.2% compared to $106.7 million in the] []

EVK [Ever-Glory International] 8-K: NANJING, China, Nov. 13, 2014 /PRNewswire/ — Ever-Glory

[NANJING, China, Nov. 13, 2014 /PRNewswire/ -- Ever-Glory International Group, Inc. (the "Company" or "Ever-Glory") (NYSE MKT: EVK), a leading apparel supply chain manager and retailer based in China, today reported its financial results for the third quarter ended September 30, 2014. Total sales for the quarter were $139.9 million, an increase of 31.2% compared to $106.7 million in the] []

BSPM [Biostar Pharmaceuticals] 10-Q: (Original Filing)

[FORM 10-Q (Mark One) x September 30, 2014 For the quarterly period ended: Or ¨ For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, INC. Maryland 20-8747899 (State or other jurisdiction of incorporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province People’s Republic of China 712046 (Zip code) 011-86-29-33686638 (Former name, former] [CERTIFICATION I, Ronghua Wang, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Biostar Pharmaceuticals, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were] [CERTIFICATION I, Qinghua Liu, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Biostar Pharmaceuticals, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Ronghua Wang Chief Executive Officer EX-32.1 4 ex32-1.htm EX-32.1] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Qinghua Liu, Interim Chief Financial Officer (Principal Financial and Accounting Officer) EX-32.2 5 ex32-2.htm EX-32.2]

By | 2016-03-28T18:15:59+00:00 November 14th, 2014|Categories: BSPM, Chinese Stocks, SEC Original|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals] 10-Q: FORM 10-Q (Mark One) x September 30, 2014

[FORM 10-Q (Mark One) x September 30, 2014 For the quarterly period ended: Or ¨ For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, INC. Maryland 20-8747899 (State or other jurisdiction of incorporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province People’s Republic of China 712046 (Zip code) 011-86-29-33686638 (Former name, former] [CERTIFICATION I, Ronghua Wang, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Biostar Pharmaceuticals, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were] [CERTIFICATION I, Qinghua Liu, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Biostar Pharmaceuticals, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Ronghua Wang Chief Executive Officer EX-32.1 4 ex32-1.htm EX-32.1] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Qinghua Liu, Interim Chief Financial Officer (Principal Financial and Accounting Officer) EX-32.2 5 ex32-2.htm EX-32.2]

By | 2016-03-28T18:17:33+00:00 November 14th, 2014|Categories: BSPM, Chinese Stocks, Webplus ver|Tags: , , , , , |0 Comments

CPHI [CHINA PHARMA] 10-Q: (Original Filing)

[o Large accelerated filer o Accelerated filer o Non-accelerated filer (Do not check if a smaller reporting company)] [CERTIFICATION OF OF THE SARBANES-OXLEY ACT OF 2002 I, Zhilin Li certify that: 1. I have reviewed this report on Form 10-Q of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER OF THE SARBANES-OXLEY ACT OF 2002 I, Zhilin Li, certify that: 1. I have reviewed this report on Form 10-Q of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made,] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: November 14, 2014 President and Chief Executive Officer (principal financial officer and principal accounting officer) EX-32.1 4 cphi10qex321093014.htm]

By | 2016-03-28T19:32:05+00:00 November 14th, 2014|Categories: Chinese Stocks, CPHI, SEC Original|Tags: , , , , , |0 Comments
Skip to toolbar